Scientists at the Oregon Health & Science University and the AIDS and Cancer Virus Program of the Frederick National Laboratory for Cancer Research have used a novel vaccine approach to achieve a “functional cure” and apparent eradication of infection with a monkey version of the AIDS virus.

Scientists at NCI and Frederick National Laboratory for Cancer Research (FNLCR) are partnering with the Lustgarten Foundation to test whether a vitamin D derivative will make a difference when combined with a conventional anticancer drug in treating tumors of the pancreas.

For the past 16 years, the annual Spring Research Festival has been sponsored by NCI at Frederick and Fort Detrick to acquaint fellow researchers, students, and the community at large with the important discoveries being made at this facility to fight cancer, AIDS, and other infectious diseases.

Deborah Morrison, Ph.D., laboratory chief, Laboratory of Cell and Developmental Signaling, Center for Cancer Research (CCR), received an NIH Director’s Award in June “for major breakthroughs in elucidating the mechanisms of Ras/Raf signaling that will be critical for diagnosis and treatment of disease,” according to the NIH Director’s Awards Ceremony brochure. She was nominated by Ira Daar, Ph.D., senior investigator, Developmental Signal Transduction Section, Laboratory of Cell and Developmental Signaling, CCR.

The human immunodeficiency virus (HIV) targets specific immune cells in the body known as macrophages because these are the cells that eliminate foreign material such as bacteria or viruses. HIV is able to reproduce and spread throughout the body if it can avoid destruction by macrophages. A recent study by Lue Dai, Ph.D., and colleagues revealed that the human cytokine IL-27 helps promote the body’s production of macrophages that are resistant to HIV.